Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp is experiencing significant revenue growth, with Surgical Aesthetics revenue projected to reach between $43.0 million and $45.0 million, marking a 14% increase year-over-year at the midpoint. The company's overall full-year revenue guidance has been raised to between $50.5 million and $52.5 million, driven by strong demand trends and the successful launch of its AYON Body Contouring System. Additionally, the growing adoption of GLP-1 weight-loss drugs has contributed to increased demand for surgical-quality skin procedures, enhancing Apyx's market potential and overall financial outlook.

Bears say

Apyx Medical Corp faces challenges with its Original Equipment Manufacturing (OEM) segment, which is projected to generate approximately $7.5 million, a reduction from the previous guidance of $8.0 million due to decreased sales volumes to existing customers. The stock has been negatively impacted by an FDA warning letter issued in March 2022 and market pressures related to increased GLP-1 usage, contributing to sustained volatility in its Surgical Aesthetics segment, which typically accounts for over 80% of its revenue. Additionally, the company's cash position declined from $29.3 million at the end of the second quarter of 2025 to $25.1 million at the end of the third quarter, further reflecting financial instability amid ongoing regulatory and market challenges.

APYX has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Buy based on their latest research and market trends.

According to 2 analysts, APYX has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.